Feed / JAZZ

Jazz Pharmaceuticals plc

JAZZ

Healthcare · 254.27 +2.2% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Jazz Pharmaceuticals plc's move is being confirmed by its market group.

JAZZ accounts for 16.7% of the group's measured movement across 8.4 effective names. raw member direction is mixed; 8 of 12 session-normalized paths align to the upside. Capital-flow agreement is 17%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveAligned contributor#2 of 12 by movement share
Group movement share16.7%Absolute path energy—not portfolio weight
Relative path+2.26%aligned
Effective breadth8.4 / 12broad
Relative alignment8/12upside path · 4 counter-moving
Capital-flow agreement17%not yet clean
SEQUENCE READ

KRYS moved materially before JAZZ. JAZZ crossed its material path threshold at 15:35 ET. CLDX, IMNM, MIRM followed.

What changed
  • Revenue increased 15.5% versus the comparable filing period.
EVIDENCE COVERAGE

14 of 18 members in Biotech Rare Diseases are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 12 of 18 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as ROIV begins moving with the group.

Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.

Watch this read

Who this business touches

The relationships behind JAZZ

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AMRXAmneal Pharmaceuticals, Inc.customerAug 6, 2025 ▾

“Specifically, a wholly owned subsidiary of Hikma launched its AG version of sodium oxybate in January 2023 and Amneal launched its AG version of sodium oxybate in July 2023.”

ALKSAlkermes plcpartnerFeb 24, 2026 ▾

“In addition, Alkermes acquired Avadel in February 2026, which may strengthen both companies and 23 Table of Contents we may experience increased competition from the combined company.”

Depended on by

ALKSAlkermes plcpartnerMay 5, 2026 ▾

“Pursuant to the settlement and license agreement entered into between Jazz Pharmaceuticals entities and Avadel entities in October 2025 (the “Avadel Settlement Agreement”), from October 1, 2025, Jazz receives a royalty of 3.85% (subject to certain adjustments…”

Filing peers

XENEPRAXALKS

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

JAZZ is currently a Leader in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.